Brief: Evelo Biosciences Expands Clinical Programs And Provides 2021 Guidance

Evelo Biosciences

07/01/2021 12:19

Jan 7 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * EVELO BIOSCIENCES EXPANDS CLINICAL PROGRAMS AND PROVIDES
2021
GUIDANCE ON KEY MILESTONES
    * EVELO BIOSCIENCES INC - EXPAND EDP1815 PHASE 2 PROGRAM TO
INCLUDE ATOPIC DERMATITIS; INTERIM CLINICAL RESULTS EXPECTED IN
1Q 2022
    * EVELO BIOSCIENCES INC - ACCELERATE DELIVERY OF INTERIM
CLINICAL
DATA FROM EDP1815 PHASE 2 PSORIASIS TRIAL TO 2Q 2021; FULL
DATASET EXPECTED 2H 2021
    * EVELO BIOSCIENCES INC - ADVANCE NOVEL ANTI-INFLAMMATORY
PRODUCT
CANDIDATE EDP1867 IN ATOPIC DERMATITIS INTO CLINIC IN 1Q 2021;
DATA EXPECTED 4Q 2021

Source text for Eikon:  ID:nGNX5m6C6p 
Further company coverage:  EVLO.O 

 ((Reuters.Briefs@thomsonreuters.com;))